Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)

Background: This study was conducted to evaluate CD30 expression in minimum residual disease after chemotherapy in B-acute lymphoblastic leukemia (B-ALL). Materials and Methods: This was a cross-sectional study on 30 new cases of B-ALL between 2018 and 2019. We checked CD30 expressions in fresh bone...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amirhossein Kazemian, Pardis Nematollahi
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer Medknow Publications 2021
Materias:	acute lymphoblastic leukemia b lymphoblastic leukemia cd30 flow cytometry minimum residual disease Medicine R
Acceso en línea:	https://doaj.org/article/01630613ecdf4e838d251897df95beff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01630613ecdf4e838d251897df95beff
record_format	dspace
spelling	oai:doaj.org-article:01630613ecdf4e838d251897df95beff2021-11-12T10:25:23ZEvaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)1735-19951735-713610.4103/jrms.JRMS_1024_20https://doaj.org/article/01630613ecdf4e838d251897df95beff2021-01-01T00:00:00Zhttp://www.jmsjournal.net/article.asp?issn=1735-1995;year=2021;volume=26;issue=1;spage=90;epage=90;aulast=Kazemianhttps://doaj.org/toc/1735-1995https://doaj.org/toc/1735-7136Background: This study was conducted to evaluate CD30 expression in minimum residual disease after chemotherapy in B-acute lymphoblastic leukemia (B-ALL). Materials and Methods: This was a cross-sectional study on 30 new cases of B-ALL between 2018 and 2019. We checked CD30 expressions in fresh bone marrow aspirates by flow cytometry. After 28 days of routine chemotherapy, we calculated minimal residual disease in CD30 positive and negative patients and compare them by Kolmogorov–Smirnov test. Results: Thirty patients with B-ALL with a mean age of 15.62 ± 20.488 were included in the study. CD30 marker was positive in about 10 patients and was negative in about 20 participants. Mean blast count in baseline in CD30 positive group was 77 ± 7.88%, in negative group was 76.3 ± 17.78 % (P = 0.292). After 28 days of chemotherapy mean minimal residual disease (MRD) was 1.07 ± 3.754 in the negative group, 0.12 ± 0.034 in the positive group (P = 0.025). Conclusion: Lower MRD on day 28 after chemotherapy was seen in B-ALL patients with baseline CD30 expression.Amirhossein KazemianPardis NematollahiWolters Kluwer Medknow Publicationsarticleacute lymphoblastic leukemiab lymphoblastic leukemiacd30flow cytometryminimum residual diseaseMedicineRENJournal of Research in Medical Sciences, Vol 26, Iss 1, Pp 90-90 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acute lymphoblastic leukemia b lymphoblastic leukemia cd30 flow cytometry minimum residual disease Medicine R
spellingShingle	acute lymphoblastic leukemia b lymphoblastic leukemia cd30 flow cytometry minimum residual disease Medicine R Amirhossein Kazemian Pardis Nematollahi Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
description	Background: This study was conducted to evaluate CD30 expression in minimum residual disease after chemotherapy in B-acute lymphoblastic leukemia (B-ALL). Materials and Methods: This was a cross-sectional study on 30 new cases of B-ALL between 2018 and 2019. We checked CD30 expressions in fresh bone marrow aspirates by flow cytometry. After 28 days of routine chemotherapy, we calculated minimal residual disease in CD30 positive and negative patients and compare them by Kolmogorov–Smirnov test. Results: Thirty patients with B-ALL with a mean age of 15.62 ± 20.488 were included in the study. CD30 marker was positive in about 10 patients and was negative in about 20 participants. Mean blast count in baseline in CD30 positive group was 77 ± 7.88%, in negative group was 76.3 ± 17.78 % (P = 0.292). After 28 days of chemotherapy mean minimal residual disease (MRD) was 1.07 ± 3.754 in the negative group, 0.12 ± 0.034 in the positive group (P = 0.025). Conclusion: Lower MRD on day 28 after chemotherapy was seen in B-ALL patients with baseline CD30 expression.
format	article
author	Amirhossein Kazemian Pardis Nematollahi
author_facet	Amirhossein Kazemian Pardis Nematollahi
author_sort	Amirhossein Kazemian
title	Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
title_short	Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
title_full	Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
title_fullStr	Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
title_full_unstemmed	Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
title_sort	evaluation of cd30 expression in b all and its correlation with mrd(minimum residual disease)
publisher	Wolters Kluwer Medknow Publications
publishDate	2021
url	https://doaj.org/article/01630613ecdf4e838d251897df95beff
work_keys_str_mv	AT amirhosseinkazemian evaluationofcd30expressioninballanditscorrelationwithmrdminimumresidualdisease AT pardisnematollahi evaluationofcd30expressioninballanditscorrelationwithmrdminimumresidualdisease
_version_	1718430969608798208

Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)

Ejemplares similares